Protea Biosciences Group Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Protea Biosciences Group Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7571
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Protea Biosciences Group Inc (Protea) is a biotechnology company that develops mass spectometry solutions. The company offers technology for identification, characterization, and quantitation of biologically-important molecules for pharmaceutical development, research, and diagnostic applications. Its products include functionalized pipette tips and plates, gel protein separation and recovery, protein sample preparation, amplus HPLC columns and mass spectrometry standards, among others. Protea’s services include bioanalytical services and mass spec imaging services. The company’s bioanalytical services include biomarker discovery, advanced proteomics and protein, biotherapeutic characterization and peptide quantitation, among others. It also provides label free imaging, translational, and drug and metabolite distribution. The company serves pharmaceutical, clinical, academic and industrial research. Protea is headquartered in Morgantown, West Virginia, the US.

Protea Biosciences Group Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Protea Biosciences Group Inc, Medical Devices Deals, 2012 to YTD 2018 10
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Protea Biosciences Enters into Co-Marketing Agreement with Proteos 12
Protea Biosciences Enters into Agreement with Agilent Technologies 13
Protea Biosciences Enters Into Research Agreement With Virginia Commonwealth University For Molecular Imaging Techniques 14
Waters Enters Into Co-Marketing Agreement With Protea Biosciences Group For LASEI DP-1000 15
Protea Biosciences Group Enters Into Co-Development Agreement With Oak Ridge National Lab 16
Licensing Agreements 17
Protea Biosciences Enters into License Agreement with George Washington University 17
Equity Offering 18
Protea Biosciences Files Registration Statement to Raise up to USD17.3 Million in Public Offering of Shares 18
Protea Biosciences Group Raises USD0.6 Million in Private Placement 19
Protea Biosciences Raises USD0.98 Million in Public Offering of Units 20
Protea Biosciences Raises USD2.53 Million in Public Offering of Units 21
Protea Biosciences Group Completes Private Placement Of Shares For US$0.7 Million 22
Protea Biosciences Completes Private Placement Of Shares For US$0.5 Million 23
Debt Offering 24
Protea Biosciences Raises USD0.1 Million in Private Placement of Debentures 24
Protea Biosciences Raises USD1.61 Million in Private Placement of Debentures 25
Protea Biosciences Raises USD2 Million in Private Placement of Debentures 26
Protea Biosciences Group Completes Private Placement Of Debt Securities For US$0.3 Million 27
Asset Transactions 28
Purdue University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 28
Princeton University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 29
Acquisition 30
Protea Biosciences to Acquire vivoPharm for USD11.2 Million 30
AzurRx BioPharma Acquires ProteaBio Europe for USD7 Million 32
Protea Biosciences Group Inc – Key Competitors 34
Protea Biosciences Group Inc – Key Employees 35
Protea Biosciences Group Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Apr 18, 2017: Protea Announces 2016 Year End Results 37
Product News 38
Jun 21, 2017: Protea introduces new molecular imaging technology 38
Other Significant Developments 39
Jul 12, 2017: Protea Announces New Test Methods for Therapeutic Antibodies 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Key Facts 2
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Protea Biosciences Group Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Protea Biosciences Group Inc, Medical Devices Deals, 2012 to YTD 2018 10
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Protea Biosciences Enters into Co-Marketing Agreement with Proteos 12
Protea Biosciences Enters into Agreement with Agilent Technologies 13
Protea Biosciences Enters Into Research Agreement With Virginia Commonwealth University For Molecular Imaging Techniques 14
Waters Enters Into Co-Marketing Agreement With Protea Biosciences Group For LASEI DP-1000 15
Protea Biosciences Group Enters Into Co-Development Agreement With Oak Ridge National Lab 16
Protea Biosciences Enters into License Agreement with George Washington University 17
Protea Biosciences Files Registration Statement to Raise up to USD17.3 Million in Public Offering of Shares 18
Protea Biosciences Group Raises USD0.6 Million in Private Placement 19
Protea Biosciences Raises USD0.98 Million in Public Offering of Units 20
Protea Biosciences Raises USD2.53 Million in Public Offering of Units 21
Protea Biosciences Group Completes Private Placement Of Shares For US$0.7 Million 22
Protea Biosciences Completes Private Placement Of Shares For US$0.5 Million 23
Protea Biosciences Raises USD0.1 Million in Private Placement of Debentures 24
Protea Biosciences Raises USD1.61 Million in Private Placement of Debentures 25
Protea Biosciences Raises USD2 Million in Private Placement of Debentures 26
Protea Biosciences Group Completes Private Placement Of Debt Securities For US$0.3 Million 27
Purdue University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 28
Princeton University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 29
Protea Biosciences to Acquire vivoPharm for USD11.2 Million 30
AzurRx BioPharma Acquires ProteaBio Europe for USD7 Million 32
Protea Biosciences Group Inc, Key Competitors 34
Protea Biosciences Group Inc, Key Employees 35
Protea Biosciences Group Inc, Subsidiaries 36

List of Figures
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Protea Biosciences Group Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Protea Biosciences Group Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PNM Resources Inc (PNM):企業の財務・戦略的SWOT分析
    PNM Resources Inc (PNM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Bridgestone Corporation:企業の戦略・SWOT・財務情報
    Bridgestone Corporation - Strategy, SWOT and Corporate Finance Report Summary Bridgestone Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • InVitae Corp (NVTA):医療機器:M&Aディール及び事業提携情報
    Summary Invitae Corp (Invitae), formerly Locus Development Inc, is a genetic information company which processes DNA-containing samples, analyzes information about patient-specific genetic variation and generates test reports for clinicians and their patients. The company’s portfolio of diagnostic t …
  • Sanchez Energy Corp (SN):企業の財務・戦略的SWOT分析
    Summary Sanchez Energy Corp (Sanchez) is an independent exploration and production company that acquires and develops unconventional oil and natural gas resources. It operates in the horizontal development of resources from the Eagle Ford Shale in South Texas. The company also holds an undeveloped a …
  • Trammo Inc:企業の戦略的SWOT分析
    Trammo Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Oman Oil Company SAOC:企業のM&A・事業提携・投資動向
    Oman Oil Company SAOC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Oman Oil Company SAOC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • CITIC Pacific Limited:戦略・SWOT・企業財務分析
    CITIC Pacific Limited - Strategy, SWOT and Corporate Finance Report Summary CITIC Pacific Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Symrise AG (SY1):企業の財務・戦略的SWOT分析
    Symrise AG (SY1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Torrent Power Ltd (TORNTPOWER):企業の財務・戦略的SWOT分析
    Torrent Power Ltd (TORNTPOWER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Arqvia Group Ltd:企業の戦略・SWOT・財務分析
    Arqvia Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Arqvia Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Grid2020, Inc.-エネルギー分野:企業M&A・提携分析
    Summary Grid2020, Inc. (Grid2020) is a provider of smart grid solutions. The company offers an integrated distribution transformer monitoring solutions under the brand Optanode. The Optanode product family consists of sensors and smart analytics software and provides information about the distributi …
  • City National Wealth Management:企業の戦略・SWOT・財務分析
    City National Wealth Management - Strategy, SWOT and Corporate Finance Report Summary City National Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Ashok Leyland Limited:企業の戦略・SWOT・財務情報
    Ashok Leyland Limited - Strategy, SWOT and Corporate Finance Report Summary Ashok Leyland Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • CellSeed Inc (7776):企業の製品パイプライン分析
    Summary CellSeed Inc (CellSeed) is a developer of regenerative medicine. The company’s products include epithelial cell sheet for corneal regeneration, regenerated cardiac patch, epithelial cell sheet for esophageal regeneration, cell sheet for periodontal tissue regeneration and regenerated cartila …
  • Tata Chemicals Ltd (TATACHEM):企業の財務・戦略的SWOT分析
    Summary Tata Chemicals Ltd (TCL) is a chemical company engaged in offering industry, living, and farm essential chemicals. The company's products include dals, consumer salt, water purifier, soda ash, spices, sodium bicarbonate, allied chemicals, industrial salt, customized fertilizers, cement, fert …
  • Kao Corporation:企業の戦略・SWOT・財務情報
    Kao Corporation - Strategy, SWOT and Corporate Finance Report Summary Kao Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Evertec Inc (EVTC):企業の財務・戦略的SWOT分析
    Summary Evertec Inc (Evertec) is a technology and communication company that offers transaction processing services. The company’s services include payment processing, merchant acquiring and business process management. Its payment processing services comprise card issuing and acquiring processing; …
  • PDL BioPharma Inc (PDLI)-医療機器分野:企業M&A・提携分析
    Summary PDL BioPharma Inc (PDL) formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets that include Queen et al. patents and license agreements with various pharmaceutical and biotechnology companies, and royalty and other acquired assets. It offers financing solutions …
  • Interface Biologics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Interface Biologics Inc (IBI) is a medical device company that develops transformative biomedical polymer technologies. The company offers anti-thrombogenic and combination drug delivery devices. Its anti-thrombogenic additives reduce thrombosis in blood contacting medical devices and polyme …
  • Ocular Therapeutix Inc (OCUL):企業の製品パイプライン分析2018
    Summary Ocular Therapeutix Inc (Ocular), formerly I-Therapeutix Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for diseases using hydrogel platform technology. The company’s products include DEXTENZA, sustained release travoprost and posterior …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆